AR119234A1 - Derivados de imidazo[1,2-a]piridinilo y su uso en el tratamiento de enfermedades - Google Patents
Derivados de imidazo[1,2-a]piridinilo y su uso en el tratamiento de enfermedadesInfo
- Publication number
- AR119234A1 AR119234A1 ARP200101780A ARP200101780A AR119234A1 AR 119234 A1 AR119234 A1 AR 119234A1 AR P200101780 A ARP200101780 A AR P200101780A AR P200101780 A ARP200101780 A AR P200101780A AR 119234 A1 AR119234 A1 AR 119234A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- independently selected
- membered
- nitrogen
- oxygen
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 5
- 201000010099 disease Diseases 0.000 title abstract 4
- 125000004178 (C1-C4) alkyl group Chemical class 0.000 abstract 23
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 18
- 229910052757 nitrogen Inorganic materials 0.000 abstract 17
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 16
- 125000005842 heteroatom Chemical group 0.000 abstract 16
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 16
- 229910052760 oxygen Chemical group 0.000 abstract 16
- 239000001301 oxygen Chemical group 0.000 abstract 16
- 125000000623 heterocyclic group Chemical group 0.000 abstract 15
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 10
- 229920006395 saturated elastomer Polymers 0.000 abstract 10
- 125000005843 halogen group Chemical group 0.000 abstract 8
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 5
- 125000001424 substituent group Chemical group 0.000 abstract 5
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 4
- 125000000217 alkyl group Chemical group 0.000 abstract 4
- 229910052736 halogen Chemical group 0.000 abstract 4
- 229910052739 hydrogen Inorganic materials 0.000 abstract 4
- 239000001257 hydrogen Substances 0.000 abstract 4
- 125000004043 oxo group Chemical group O=* 0.000 abstract 4
- 229910052717 sulfur Inorganic materials 0.000 abstract 4
- 239000011593 sulfur Chemical group 0.000 abstract 4
- 125000004122 cyclic group Chemical group 0.000 abstract 3
- 150000002367 halogens Chemical group 0.000 abstract 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 3
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- -1 imidazo[1,2-a]pyridinyl Chemical class 0.000 abstract 2
- 150000002825 nitriles Chemical class 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 125000006526 (C1-C2) alkyl group Chemical group 0.000 abstract 1
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 208000020084 Bone disease Diseases 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 125000004429 atom Chemical group 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 125000002837 carbocyclic group Chemical group 0.000 abstract 1
- 210000003169 central nervous system Anatomy 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 125000006413 ring segment Chemical group 0.000 abstract 1
- 208000017520 skin disease Diseases 0.000 abstract 1
- 230000009885 systemic effect Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Psychology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
Abstract
La presente hace referencia a derivados de imidazo[1,2-a]piridinilo de fórmula (1), o sales farmacéuticamente aceptables de estos, en los cuales todas las variables son tal como se definen en la memoria descriptiva, capaces de modular la actividad de IRAK4. Además, la presente proporciona un método para fabricar compuestos de la presente y métodos para su uso terapéutico. La presente también proporciona métodos para su preparación, para su uso médico, en particular, para su uso en el tratamiento y el control de enfermedades o trastornos que incluyen una enfermedad inflamatoria, una enfermedad autoinmunitaria, cáncer, una enfermedad cardiovascular, una enfermedad del sistema nervioso central, una enfermedad de la piel, una afección y enfermedad oftálmica, y una enfermedad ósea. Reivindicación 1: Un compuesto de fórmula (1) o una sal farmacéuticamente aceptable de este, en donde: R¹ se selecciona del grupo que consiste en halo, alquilo C₁₋₅, cicloalquilo C₃₋₆, -alquilo C₁₋₂-cicloalquilo C₃₋₆, un heterociclo de 4 a 7 miembros completamente saturado que contiene 1 a 2 heteroátomos seleccionados de forma independiente de nitrógeno, azufre y oxígeno, -alquilo C₁₋₂-heterociclo C₄₋₇, en donde el heterociclo C₄₋₇ puede estar completamente o parcialmente saturado y contiene 1 a 2 heteroátomos seleccionados de forma independiente de nitrógeno, azufre y oxígeno, -alquilo C₁₋₄-O-alquilo C₁₋₂, un anillo carbocíclico puenteado de 5 a 8 miembros completamente saturado, un sistema de anillo heterocíclico puenteado de 5 a 8 miembros completamente saturado con 1 a 2 heteroátomos seleccionados de forma independiente de nitrógeno y oxígeno, un sistema de anillo heterobicíclico fusionado de 5 a 10 miembros con 1 a 2 heteroátomos seleccionados de forma independiente de nitrógeno y oxígeno y un sistema de anillo heterobicíclico espiro de 5 a 10 miembros con 1 a 2 heteroátomos seleccionados de forma independiente de nitrógeno y oxígeno, en donde R¹ puede estar opcionalmente sustituido con 1, 2 ó 3 sustituyentes R¹ᵃ seleccionados de forma independiente de halo, nitrilo, oxo, alquilo C₁₋₄ sustituido con halo, alquilo C₁₋₄ sustituido con hidroxi, alquilo C₁₋₄, heterociclo C₄₋₇ que contiene 1 a 2 heteroátomos seleccionados de forma independiente de nitrógeno y oxígeno, alquilo C₁₋₄-O-alquilo C₁₋₂, hidroxilo y alcoxi C₁₋₄; R² es hidrógeno, alquilo C₁₋₄ o halógeno; R³ se selecciona del grupo que consiste en i) un heteroarilo de 5 ó 6 miembros con 1 a 3 heteroátomos seleccionados de forma independiente de nitrógeno, oxígeno y azufre, y dicho heteroarilo está opcionalmente sustituido con 1 a 3 R⁴; ii) fenilo opcionalmente sustituido con 1 a 3 R⁴; iii) un heterociclo de 5 - 6 miembros parcial o completamente saturado con 1 a 2 heteroátomos seleccionados de forma independiente de oxígeno y nitrógeno, y dicho heterociclo puede estar opcionalmente sustituido con 1 a 3 R⁴; iv) un cicloalquilo C₃₋₆ parcial o completamente saturado que puede estar opcionalmente sustituido con 1 a 3 R⁴; v) un sistema de anillo heterobicíclico de 7 a 10 miembros fusionado con 1, 2 ó 3 heteroátomos seleccionados de forma independiente de nitrógeno y oxígeno, y dicho sistema de anillo está opcionalmente sustituido con 1 a 3 R⁴; y vi) un sistema de anillo bicíclico de 7 a 10 miembros fusionado, y dicho sistema de anillo está opcionalmente sustituido con 1 a 3 R⁴; X¹ o X² puede ser N; R⁵ se selecciona de halógeno, alquilo C₁₋₄, nitrilo y -OR⁶, en donde el alquilo C₁₋₄ está opcionalmente sustituido con alcoxi C₁₋₄; R⁶ es hidrógeno, alquilo C₁₋₅, cicloalquilo C₃₋₆, un heterociclo de 4 a 7 miembros parcialmente o completamente saturado que contiene 1 ó 2 heteroátomos seleccionados de nitrógeno y oxígeno, un anillo carbocíclico espiro de 5 a 10 miembros y un sistema de anillo heterobicíclico espiro de 5 a 10 miembros con 1 a 2 heteroátomos seleccionados de forma independiente de nitrógeno y oxígeno, en donde el alquilo C₁₋₅ representado por R⁶ está opcionalmente sustituido con 1 a 3 sustituyentes R⁶ᵃ seleccionados de forma independiente de halógeno, hidroxilo, alcoxi C₁₋₄, alcoxi C₁₋₄ sustituido con halo, cicloalquilo C₃₋₆, fenilo, un heterociclo de 4 a 7 miembros parcialmente o completamente saturado que contiene 1 ó 2 heteroátomos seleccionados de nitrógeno y oxígeno, un sistema de anillo heterocíclico puenteado de 5 a 8 miembros completamente saturado con 1 a 2 heteroátomos seleccionados de forma independiente de nitrógeno y oxígeno; el cicloalquilo C₃₋₆ representado por R⁶ está opcionalmente sustituido con 1 a 3 sustituyentes R⁶ᵇ seleccionados de forma independiente de halo, alquilo C₁₋₄, alquilo C₁₋₄ sustituido con halo, y alcoxi C₁₋₄; el heterociclo de 4 a 7 miembros parcialmente o completamente saturado, el anillo carbocíclico espiro de 5 a 10 miembros y el sistema de anillo heterobicíclico espiro de 5 a 10 miembros representado por R⁶ está opcionalmente sustituido con 1 a 3 sustituyentes R⁶ᶜ seleccionados de forma independiente de alquilo C₁₋₄ y oxo, y en donde dicho cicloalquilo C₃₋₆, fenilo, heterociclo de 4 a 7 miembros parcialmente o completamente saturado representados por R⁶ᵃ están opcionalmente sustituidos con 1 a 3 R⁷; cada R⁷ se selecciona de forma independiente de oxo, halo, alquilo C₁₋₄ sustituido con halo y alquilo C₁₋₄; en cada aparición, R⁴ se selecciona de forma independiente de CN, hidroxilo, alquilo C₁₋₄, alquilo C₁₋₄ sustituido con CN, oxo, halo, alquilo C₁₋₄ sustituido con halo, alcoxi C₁₋₄-alquilo C₁₋₄, -NR⁸R⁹, alcoxi C₁₋₄, alcoxi C₁₋₄-alcoxi C₁₋₄, alquilo C₁₋₄ sustituido con hidroxi, alcoxi C₁₋₄ sustituido con halo, cicloalquilo C₃₋₆, alquilo -C₁₋₄-cicloalquilo C₃₋₆, C(O)NR¹⁰R¹¹, un heterociclo C₄₋₇, y un heteroarilo de 5 ó 6 miembros con 1 a 2 heteroátomos seleccionados de forma independiente de nitrógeno, oxígeno y azufre, dicho cicloalquilo C₃₋₆ y heteroarilo pueden estar opcionalmente sustituidos con 1 a 2 sustituyentes seleccionados de forma independiente del grupo que consiste en alquilo C₁₋₄, hidroxilo y halógeno; o dos grupos R⁴ en el mismo átomo pueden formar un cicloalquilo C₃₋₆, o dos grupos R⁴ en átomos anulares adyacentes pueden formar fenilo, carbociclo C₄₋₆, heterociclo C₄₋₆, o un sistema de anillo puenteado de 7 miembros que opcionalmente tiene 1 heteroátomo seleccionado de nitrógeno y oxígeno, en donde dicho fenilo, cicloalquilo C₃₋₆, carbociclo C₄₋₆ y heterociclo C₄₋₆ pueden estar opcionalmente sustituidos con 1 a 2 alquilo C₁₋₄, halo o alquilo C₁₋₄ sustituido con halo; cada R⁸ y R⁹ se seleccionan de forma independiente de hidrógeno, -C(O)alquilo C₁₋₄ y alquilo C₁₋₄; o R⁸ y R⁹ se pueden combinar para formar un anillo saturado de 4 a 6 miembros que contiene opcionalmente un heteroátomo adicional seleccionado de nitrógeno u oxígeno, en donde dicho nitrógeno adicional puede estar opcionalmente sustituido con alquilo C₁₋₄; y cada uno de R¹⁰ y R¹¹ se selecciona de forma independiente de hidrógeno y alquilo C₁₋₄.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962867589P | 2019-06-27 | 2019-06-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR119234A1 true AR119234A1 (es) | 2021-12-01 |
Family
ID=71528117
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP200101780A AR119234A1 (es) | 2019-06-27 | 2020-06-24 | Derivados de imidazo[1,2-a]piridinilo y su uso en el tratamiento de enfermedades |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US20230087118A1 (es) |
| EP (1) | EP3990454A1 (es) |
| JP (1) | JP7576581B2 (es) |
| KR (1) | KR20220027196A (es) |
| CN (1) | CN114245796B (es) |
| AR (1) | AR119234A1 (es) |
| AU (1) | AU2020301230A1 (es) |
| BR (1) | BR112021026350A2 (es) |
| CA (1) | CA3145040A1 (es) |
| CL (1) | CL2021003452A1 (es) |
| CO (1) | CO2022000659A2 (es) |
| CR (1) | CR20220037A (es) |
| IL (1) | IL289164A (es) |
| JO (1) | JOP20210322A1 (es) |
| MA (1) | MA56390A (es) |
| MX (1) | MX2021015498A (es) |
| PE (1) | PE20220578A1 (es) |
| PH (1) | PH12021553223A1 (es) |
| TW (1) | TW202115075A (es) |
| UY (1) | UY38766A (es) |
| WO (1) | WO2020263980A1 (es) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3911652A1 (en) * | 2019-01-18 | 2021-11-24 | Biogen MA Inc. | Imidazo[1,2-a]pyridinyl derivatives as irak4 inhibitors |
| US11866405B2 (en) | 2020-12-10 | 2024-01-09 | Astrazeneca Ab | Substituted indazoles as IRAK4 inhibitors |
| WO2022140425A1 (en) * | 2020-12-22 | 2022-06-30 | Biogen Ma Inc. | Imidazo[1,2-a]pyridine derivatives as irak4 inhibitors and their use in the treatment of disease |
| KR20230134499A (ko) * | 2020-12-22 | 2023-09-21 | 바이오젠 엠에이 인코포레이티드 | Irak4 억제제로서의 2h-인다졸 유도체 및 질환의 치료에서의그의 용도 |
| US20240287064A1 (en) * | 2021-06-21 | 2024-08-29 | Wuhan Humanwell Innovative Drug Research and Development Center Limited Company | Tricyclic compound used as gpr84 antagonist |
| MX2024000395A (es) * | 2021-07-07 | 2024-04-05 | Biogen Ma Inc | Compuestos para la degradacion selectiva de las proteinas irak4. |
| EP4479137A1 (en) | 2022-02-14 | 2024-12-25 | Astrazeneca AB | Irak4 inhibitors |
| PT4387730T (pt) * | 2022-09-08 | 2025-08-27 | Redx Pharma Ltd | Formas sólidas de um inibidor rock |
| EP4389747A1 (en) * | 2022-12-21 | 2024-06-26 | Dark Blue Therapeutics Ltd | Imidazo[1,2-a]pyridine and imidazo[1,2-a]pyrazine derivatives as mllt1 and mllt3 inhibitors |
| EP4638447A1 (en) * | 2022-12-21 | 2025-10-29 | Dark Blue Therapeutics Ltd | Imidazo[1,2-a]pyridine and imidazo[1,2-a]pyrazine derivatives as mllt1 and mllt3 inhibitors |
| KR20260004434A (ko) * | 2023-04-24 | 2026-01-08 | 상하이 에스아이엠알 바이오테크놀로지 컴퍼니 리미티드 | 이미다조피리딘 또는 이미다조피라진 화합물, 이의 제조 방법, 약학 조성물 및 용도 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004078163A2 (en) | 2003-02-28 | 2004-09-16 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
| EP1476449A1 (en) * | 2002-02-19 | 2004-11-17 | PHARMACIA & UPJOHN COMPANY | Fused bicyclic-n-bridged-heteroaromatic carboxamides for the treatment of disease |
| EP2593457B1 (en) * | 2010-07-13 | 2017-08-23 | F. Hoffmann-La Roche AG | Pyrazolo[1,5a]pyrimidine and thieno[3,2b]pyrimidine derivatives as irak4 modulators |
| JP6556146B2 (ja) * | 2014-08-26 | 2019-08-07 | 武田薬品工業株式会社 | 複素環化合物 |
| US10059708B2 (en) * | 2016-04-26 | 2018-08-28 | Northwestern University | Therapeutic targeting of the interleukin 1 receptor-associated kinase 4 (IRAK4) in leukemias characterized by rearrangements in the mixed lineage leukemia gene (MLL-r) |
| JP2020524692A (ja) * | 2017-06-21 | 2020-08-20 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | Ｉｒａｋ４調節因子としてのベンゾフラン |
-
2020
- 2020-06-24 KR KR1020227003151A patent/KR20220027196A/ko not_active Withdrawn
- 2020-06-24 PH PH1/2021/553223A patent/PH12021553223A1/en unknown
- 2020-06-24 WO PCT/US2020/039359 patent/WO2020263980A1/en not_active Ceased
- 2020-06-24 JP JP2021577475A patent/JP7576581B2/ja active Active
- 2020-06-24 MX MX2021015498A patent/MX2021015498A/es unknown
- 2020-06-24 CR CR20220037A patent/CR20220037A/es unknown
- 2020-06-24 BR BR112021026350A patent/BR112021026350A2/pt not_active Application Discontinuation
- 2020-06-24 JO JOP/2021/0322A patent/JOP20210322A1/ar unknown
- 2020-06-24 TW TW109121722A patent/TW202115075A/zh unknown
- 2020-06-24 MA MA056390A patent/MA56390A/fr unknown
- 2020-06-24 AR ARP200101780A patent/AR119234A1/es not_active Application Discontinuation
- 2020-06-24 UY UY0001038766A patent/UY38766A/es not_active Application Discontinuation
- 2020-06-24 CN CN202080057861.7A patent/CN114245796B/zh active Active
- 2020-06-24 CA CA3145040A patent/CA3145040A1/en active Pending
- 2020-06-24 EP EP20737851.4A patent/EP3990454A1/en not_active Withdrawn
- 2020-06-24 AU AU2020301230A patent/AU2020301230A1/en not_active Abandoned
- 2020-06-24 PE PE2021002219A patent/PE20220578A1/es unknown
- 2020-06-24 US US17/623,181 patent/US20230087118A1/en not_active Abandoned
-
2021
- 2021-12-20 IL IL289164A patent/IL289164A/en unknown
- 2021-12-22 CL CL2021003452A patent/CL2021003452A1/es unknown
-
2022
- 2022-01-25 CO CONC2022/0000659A patent/CO2022000659A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PE20220578A1 (es) | 2022-04-20 |
| IL289164A (en) | 2022-02-01 |
| WO2020263980A1 (en) | 2020-12-30 |
| JP7576581B2 (ja) | 2024-10-31 |
| AU2020301230A1 (en) | 2022-01-06 |
| MA56390A (fr) | 2022-05-04 |
| CA3145040A1 (en) | 2020-12-30 |
| WO2020263980A8 (en) | 2021-03-04 |
| BR112021026350A2 (pt) | 2022-05-10 |
| CO2022000659A2 (es) | 2022-04-29 |
| CL2021003452A1 (es) | 2022-08-19 |
| PH12021553223A1 (en) | 2022-10-17 |
| KR20220027196A (ko) | 2022-03-07 |
| CN114245796A (zh) | 2022-03-25 |
| CN114245796B (zh) | 2024-07-30 |
| US20230087118A1 (en) | 2023-03-23 |
| JOP20210322A1 (ar) | 2023-01-30 |
| CR20220037A (es) | 2022-06-03 |
| TW202115075A (zh) | 2021-04-16 |
| UY38766A (es) | 2021-01-29 |
| EP3990454A1 (en) | 2022-05-04 |
| MX2021015498A (es) | 2022-04-20 |
| JP2022539373A (ja) | 2022-09-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR119234A1 (es) | Derivados de imidazo[1,2-a]piridinilo y su uso en el tratamiento de enfermedades | |
| AR119244A1 (es) | Derivados de 2h-indazol y su uso en el tratamiento de enfermedades | |
| AR115993A2 (es) | Composiciones de pirrolopirrol como activadores de piruvato quinasa (pkr) | |
| AR107714A1 (es) | Derivados de pirazolo[1,5-a]pirazin-4-ilo | |
| AR110139A1 (es) | COMPUESTOS MONO Y ESPIROCÍCLICOS QUE CONTIENEN CICLOBUTANO Y AZETIDINA COMO INHIBIDORES DE LA INTEGRINA aV | |
| AR087760A1 (es) | Heterociclilaminas como inhibidores de pi3k | |
| AR095312A1 (es) | Compuestos de biarilamida como inhibidores de cinasa | |
| AR092108A1 (es) | Piridazina 1,4 disustituida, analogos de la misma y metodos para tratar las enfermedades relacionadas con deficiencia del smn | |
| AR114679A1 (es) | Compuestos heterocíclicos fungicidas | |
| AR087328A1 (es) | Derivados de imidazo[1,2-b]piridazina e imidazo[4,5-b]piridina como inhibidores de jak | |
| AR115015A1 (es) | Derivados de azaespiro piperazina | |
| AR096846A1 (es) | Dihidroquinoxalinonas y dihidropiridopirazinonas modificadas como inhibidores de la proteína bet | |
| AR119322A1 (es) | Compuestos derivados de 1h-pirido[1,2-a]pirazina como inhibidores de magl | |
| AR126612A1 (es) | Compuestos de heteroarilo para el tratamiento de la enfermedad de huntington | |
| AR117900A1 (es) | Pirazolopiridinas y triazolopiridinas como inhibidores de a2a / a2b | |
| AR123977A1 (es) | 1h-pirazolo[4,3-c]piridinas sustituidas y derivados como inhibidores de egfr | |
| AR121341A1 (es) | Derivados de carboxamida heteroaromática como inhibidores de la calicreína plasmática | |
| AR124451A1 (es) | DERIVADOS DE IMIDAZO[1,2-a]PIRIDINILO Y SU USO EN EL TRATAMIENTO DE ENFERMEDADES | |
| AR045006A1 (es) | Derivados de quinazolinona 5-sustituidos | |
| AR121554A1 (es) | Azálidos de urea inmunoduladores | |
| AR122143A1 (es) | Compuestos heterocíclicos | |
| AR134040A1 (es) | Moduladores de mrgprx2 y métodos de tratamiento relacionados | |
| AR120169A1 (es) | Derivados de 2-azaespiro[3.4]octano como agonistas de m4 | |
| AR129910A1 (es) | Inhibidores de tirosina cinasa 2 y usos de estos | |
| AR093763A1 (es) | Antagonistas de ccr3 de arilsulfonamida isotopicamente enriquecidas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |